Combination Product Labeling Strategy: IFU, Carton, and Drug Label Alignment in 2023 Combination Product Labeling Strategy: IFU, Carton, and Drug Label Alignment in 2023 In the context of regulatory submissions for combination products, the alignment of Instructions for Use (IFU), carton labeling, and drug labeling is critical. Combination products are composed of more than one regulated component, such as a drug and a device. Consequently, they are subject to unique regulatory pathways that require careful consideration of all labeling elements. This article serves as a step-by-step tutorial guide aimed at regulatory affairs professionals navigating the complexities of combination product approvals…

Human Factors Validation Plan for Autoinjectors and Prefilled Syringes: FDA Review Checklist in 2023 Human Factors Validation Plan for Autoinjectors and Prefilled Syringes: FDA Review Checklist in 2023 In the evolving landscape of drug-device combination products, the Human Factors Validation Plan (HFVP) stands as a pivotal component in the FDA review process. The HFVP not only facilitates the identification of potential user-related issues but also ensures the safety and effectiveness of autoinjectors and prefilled syringes. This step-by-step tutorial will guide regulatory affairs and quality assurance professionals through the necessary stages of developing an HFVP tailored for autoinjectors and prefilled syringes…

Combination Product GMP Gap Assessment: Integrating 21 CFR 210/211 with Device QSR in 2023 Combination Product GMP Gap Assessment: Integrating 21 CFR 210/211 with Device QSR in 2023 The integration of Good Manufacturing Practices (GMP) for combination products can create regulatory challenges due to their unique status that encompasses both drug and device components. It is essential for organizations to conduct a comprehensive GMP gap assessment that aligns with both the FDA regulations under 21 CFR 210/211 for drugs, and the Quality System Regulation (QSR) for devices. This article will provide a step-by-step guide to achieving such an assessment. Step…

21 CFR Part 4 Compliance Program for Combination Products: US Quality System Roadmap in 2023 21 CFR Part 4 Compliance Program for Combination Products: US Quality System Roadmap in 2023 The regulatory landscape for combination products requires meticulous planning and compliance with various guidelines. The FDA combination product consulting process involves adhering to the stipulations outlined in 21 CFR Part 4, which provides a set of standards designed to harmonize the quality system requirements across multiple product categories. This article serves as a comprehensive step-by-step tutorial guide for regulatory affairs professionals navigating the complexities of 21 CFR Part 4 compliance….

RFD (Request for Designation) Strategy for Combination Products in 2023: Evidence Pack and Timelines RFD (Request for Designation) Strategy for Combination Products in 2023: Evidence Pack and Timelines The landscape of regulatory approvals for combination products is continually evolving, particularly in the United States where the Food and Drug Administration (FDA) governs the approval processes. This article serves as a comprehensive guide for regulatory professionals focusing on the Request for Designation (RFD) strategy associated with combination products in 2023. It will outline actionable, step-by-step guidance and documentation expectations needed for successful submissions, leveraging the principles outlined in 21 CFR Part…

FDA Combination Product Consulting in 2023: PMOA, Lead Center, and Submission Route FDA Combination Product Consulting in 2023: PMOA, Lead Center, and Submission Route This comprehensive guide is designed for regulatory affairs professionals involved in navigating the complexities of the FDA combination product landscape in 2023. It focuses on key elements such as the product’s primary mode of action (PMOA), lead center designation, and the applicable submission route. Each section outlines practical steps and documentation expectations to achieve compliance and facilitate regulatory approvals. Step 1: Understanding Combination Products The FDA defines combination products as therapeutics that comprise a physical combination…

Industry Trends in Combination Product Development: 2023 and Beyond Industry Trends in Combination Product Development: 2023 and Beyond Step 1: Understanding Combination Products and Their Regulatory Framework Combination products, as defined by the FDA, are therapeutic and diagnostic products that combine drugs, devices, and/or biological products into a single product. The regulatory framework for combination products is primarily governed by 21 CFR Part 4, which outlines the requirements for these entities, addressing their development, approval, and post-marketing responsibilities. Understanding the regulatory landscape is critical for those involved in the design and submission of combination products. This integrated approach arises because…

Bridging Clinical Data Across Drug and Device for Combined Use Bridging Clinical Data Across Drug and Device for Combined Use In the evolving landscape of regulatory approvals for combination products, understanding the intricacies involved in bridging clinical data across drugs and devices is crucial for successful market entry. This comprehensive guide provides a step-by-step tutorial aimed at regulatory affairs professionals, quality assurance teams, and combination product developers focusing on the U.S. market. Ensuring compliance with FDA regulations, particularly 21 CFR Part 4, is imperative for streamlined drug-device approvals. Step 1: Identifying the Product’s Primary Mode of Action (PMOA) Determining the…

EU Notified Body Opinion Requirements for Borderline Products EU Notified Body Opinion Requirements for Borderline Products This article serves as a comprehensive resource for understanding the opinion requirements mandated by Notified Bodies regarding borderline products under the European Union Medical Device Regulation (EU MDR). Borderline products, which typically involve a combination of drug and device components, necessitate careful regulatory navigation to ensure compliance. This tutorial will guide you through each critical step in the regulatory pathway, from understanding the definitions and scope of borderline products, preparing the appropriate documentation, to effectively engaging with Notified Bodies. Understanding Borderline Products and Their…

FDA OTC Switch Risk Mitigation Strategy for US Sponsors in 2023 – Insight 7 FDA OTC Switch Risk Mitigation Strategy for US Sponsors in 2023 – Insight 7 The transition of a prescription (Rx) drug to an over-the-counter (OTC) status has significant implications for stakeholders, from regulatory professionals to market access strategists. This comprehensive guide outlines the step-by-step process of implementing a risk mitigation strategy when planning an Rx to OTC switch in compliance with FDA regulations. Emphasizing actionable strategies, we will navigate this complex regulatory landscape while ensuring adherence to ICH-GCP standards. Step 1: Understanding the Rx to OTC…